Literature DB >> 3529126

Locomotor behaviors in response to new selective D-1 and D-2 dopamine receptor agonists, and the influence of selective antagonists.

A G Molloy, K M O'Boyle, M T Pugh, J L Waddington.   

Abstract

With the introduction of the selective D-1 dopamine receptor agonist and antagonist benzazepines, especially as enantiomeric pairs, there is now a range of D-1 compounds to complement the previously available selective D-2 agents. These have been used to investigate whether sub-types of dopamine receptors might be differentially involved in locomotor behavior. Stereotyped locomotion induced by the non-selective D-2 agonist apomorphine and by the selective D-2 agonist RU 24213 were blocked by the selective D-2 antagonists metoclopramide and Ro 22-2586 [-)-piquindone). Responses to either D-2 agonist were also blocked by the selective D-1 antagonists SCH 23390 and R-(but not S-) SK&F 83566. Non-stereotyped locomotion was induced by R- but not S-SK&F 38393, a stereoselective D-1 agonist, and was blocked by SCH 23390. Responses to the D-1 agonist were also antagonised by metoclopramide. Such results suggest concerted D-1:D-2 interplay in the regulation of at least some dopaminergic behaviors, such as locomotion.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3529126     DOI: 10.1016/0091-3057(86)90262-5

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  18 in total

1.  Dopaminergic control of locomotion, mouthing, snout contact, and grooming: opposing roles of D1 and D2 receptors.

Authors:  D Eilam; H Talangbayan; G Canaran; H Szechtman
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Effect of chronic D-1 and/or D-2 dopamine antagonist treatment on SKF 38393-induced non-stereotyped grooming.

Authors:  S A Parashos; C Marin; P Barone; V Kapitzoglou-Logothetis; T N Chase
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

3.  Dopamine receptor modulation of repetitive grooming actions in the rat: potential relevance for Tourette syndrome.

Authors:  Jennifer L Taylor; Abha K Rajbhandari; Kent C Berridge; J Wayne Aldridge
Journal:  Brain Res       Date:  2010-01-28       Impact factor: 3.252

4.  Evidence for the sensitivity of operant timing behaviour to stimulation of D1 dopamine receptors.

Authors:  T H C Cheung; G Bezzina; C L Hampson; S Body; K C F Fone; C M Bradshaw; E Szabadi
Journal:  Psychopharmacology (Berl)       Date:  2007-08-01       Impact factor: 4.530

5.  Chronic administration of a selective dopamine D-2 agonist: factors determining behavioral tolerance and sensitization.

Authors:  M T Martin-Iverson; S M Stahl; S D Iversen
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

6.  Behavioural responses to the selective D1-dopamine receptor agonist R-SK&F 38393 and the selective D2-agonist RU 24213 in young compared with aged rats.

Authors:  A G Molloy; J L Waddington
Journal:  Br J Pharmacol       Date:  1988-10       Impact factor: 8.739

7.  Role of dopamine D-1 and D-2 receptor subtypes in mediating dopamine agonist effects on food consumption in rats.

Authors:  M T Martin-Iverson; C T Dourish
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

8.  Dopamine D2 agonist-induced behavioural depression is reversed by dopamine D1 agonists.

Authors:  D M Jackson; S B Ross; S R Edwards
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

9.  Biphasic locomotor effects of the dopamine D1 agonist SKF 38393 and their attenuation in non-habituated mice.

Authors:  E Tirelli; P Terry
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

10.  Evidence for a role of D1 dopamine receptors in d-amphetamine's effect on timing behaviour in the free-operant psychophysical procedure.

Authors:  T H C Cheung; G Bezzina; K Asgari; S Body; K C F Fone; C M Bradshaw; E Szabadi
Journal:  Psychopharmacology (Berl)       Date:  2006-03-15       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.